Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1978 Dec;62(6):1201–1209. doi: 10.1172/JCI109240

Circulating immune complexes in sera of children with neuroblastoma: correlation with stage of disease.

W E Brandeis, L Helson, Y Wang, R A Good, N K Day
PMCID: PMC371885  PMID: 748375

Abstract

The presence of circulating immune complexes (ICS) in freshly drawn sera of 67 children with neuroblastoma was studied by the Raji cell radioimmunoassay of Theofilopoulos et al. (J. Clin. Invest. 57: 169--182), with particular emphasis on the correlation of levels of ICS with stage of disease and changes attributable to treatment. There was a close correlation between amount of complexes and stage of disease and treatment. Levels of ICS increased as the stage of the disease advanced, and were significantly higher (P less than 0.005) in stage IV than in all other stages combined. When patients with stage IV disease were subdivided into "before," "during," and "after" treatment groups, there was a significant decrease in ICS levels as treatment progressed. Studies of complement and complement components did not give such a clear relationship. A significant decrease of hemolytic C1 values was found in patients with "active disease" compared to normal age-matched controls. Some high C3 levels, determined immunochemically, were associated with low hemolytic levels of C3, which were attributed to C3 cleavage detected by immunoelectrophoresis. Based on our survival data, ICS, which were significantly different in 20 patients now decreased when compared to those of other patients, are very valuable in the prognosis of neuroblastoma.

Full text

PDF
1201

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amlot P. L., Slaney J. M., Williams B. D. Circulating immune complexes and symptoms in Hodgkin's disease. Lancet. 1976 Feb 28;1(7957):449–451. doi: 10.1016/s0140-6736(76)91475-6. [DOI] [PubMed] [Google Scholar]
  2. BECKWITH J. B., PERRIN E. V. IN SITU NEUROBLASTOMAS: A CONTRIBUTION TO THE NATURAL HISTORY OF NEURAL CREST TUMORS. Am J Pathol. 1963 Dec;43:1089–1104. [PMC free article] [PubMed] [Google Scholar]
  3. BODIAN M. NEUROBLASTOMA: AN EVALUATION OF ITS NATURAL HISTORY AND THE EFFECTS OF THERAPY, WITH PARTICULAR REFERENCE TO TREATMENT BY MASSIVE DOSES OF VITAMIN B12. Arch Dis Child. 1963 Dec;38:606–619. doi: 10.1136/adc.38.202.606. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baldwin R. W., Price M. R., Robins R. A. Blocking of lymphocyte-mediated cytotoxicity for rat hepatoma cells by tumour-specific antigen-antibody complexes. Nat New Biol. 1972 Aug 9;238(84):185–186. doi: 10.1038/newbio238185a0. [DOI] [PubMed] [Google Scholar]
  5. Baldwin R. W., Price M. R., Robins R. A. Inhibition of hepatoma-immune lymph-node cell cytotoxicity by tumour-bearer serum, and solubilized hepatoma antigen. Int J Cancer. 1973 May;11(3):527–535. doi: 10.1002/ijc.2910110304. [DOI] [PubMed] [Google Scholar]
  6. Ballow M., Cochrane C. G. Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them. J Immunol. 1969 Nov;103(5):944–952. [PubMed] [Google Scholar]
  7. Ballow M., Shira J. E., Harden L., Yang S. Y., Day N. K. Complete absence of the third component of complement in man. J Clin Invest. 1975 Sep;56(3):703–710. doi: 10.1172/JCI108141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Beckwith J. B., Martin R. F. Observations on the histopathology of neuroblastomas. J Pediatr Surg. 1968 Feb;3(1):106–110. doi: 10.1016/0022-3468(68)90989-5. [DOI] [PubMed] [Google Scholar]
  9. Bill A. H. Immune aspects of neuroblastoma. Current information. Am J Surg. 1971 Aug;122(2):142–147. doi: 10.1016/0002-9610(71)90308-4. [DOI] [PubMed] [Google Scholar]
  10. Bill A. H., Morgan A. Evidence for immune reactions to neuroblastoma and future possibilities for investigation. J Pediatr Surg. 1970 Apr;5(2):111–116. doi: 10.1016/0022-3468(70)90266-6. [DOI] [PubMed] [Google Scholar]
  11. Carpentier N. A., Lange G. T., Fiere D. M., Fournie G. J., Lambert P. H., Miescher P. A. Clinical relevance of circulating immune complexes in human leukemia. Association in acute leukemia of the presence of immune complexes with unfavorable prognosis. J Clin Invest. 1977 Oct;60(4):874–884. doi: 10.1172/JCI108842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Carpentier N. A., Zubler R. H., Lange G. T., Lambert P. H., Miescher P. A. Complexes immuns circulants dans les leucémies humaines. Schweiz Med Wochenschr. 1976 Oct 2;106(40):1363–1364. [PubMed] [Google Scholar]
  13. Costanza M. E., Pinn V., Schwartz R. S., Nathanson L. Carcinoembryonic antigen-antibody complexes in a patient with colonic carcinoma and nephrotic syndrome. N Engl J Med. 1973 Sep 6;289(10):520–522. doi: 10.1056/NEJM197309062891007. [DOI] [PubMed] [Google Scholar]
  14. Day N. K., Geiger H., McLean R., Resnick J., Michael A., Good R. A. The association of respiratory infection, recurrent hematuria, and focal glomerulonephritis with activation of the complement system in the cold. J Clin Invest. 1973 Jul;52(7):1698–1706. doi: 10.1172/JCI107351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Day N. K., Winfield J. B., Gee T., Winchester R., Teshima H., Kunkel H. G. Evidence for immune complexes involving anti-lymphocyte antibodies associated with hypocomplementaemia in chronic lymphocytic leukaemia (CLL). Clin Exp Immunol. 1976 Nov;26(2):189–195. [PMC free article] [PubMed] [Google Scholar]
  16. Evans A. E., D'Angio G. J., Randolph J. A proposed staging for children with neuroblastoma. Children's cancer study group A. Cancer. 1971 Feb;27(2):374–378. doi: 10.1002/1097-0142(197102)27:2<374::aid-cncr2820270221>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  17. Gerson J., Evans A. E., Rosen F. S. The prognostic value of acute phase reactants in patients with neuroblastoma. Cancer. 1977 Oct;40(4):1655–1658. doi: 10.1002/1097-0142(197710)40:4<1655::aid-cncr2820400439>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  18. Götze O., Müller-Eberhard H. J. Paroxysmal nocturnal hemoglobinuria. Hemolysis initiated by the C3 activator system. N Engl J Med. 1972 Jan 27;286(4):180–184. doi: 10.1056/NEJM197201272860403. [DOI] [PubMed] [Google Scholar]
  19. Heimer R., Klein G. Circulating immune complexes in sera of patients with Burkett's lymphoma and nasopharyngeal carcinoma. Int J Cancer. 1976 Sep 15;18(3):310–316. doi: 10.1002/ijc.2910180307. [DOI] [PubMed] [Google Scholar]
  20. Hellström I. E., Hellström K. E., Pierce G. E., Bill A. H. Demonstration of cell-bound and humoral immunity against neuroblastoma cells. Proc Natl Acad Sci U S A. 1968 Aug;60(4):1231–1238. doi: 10.1073/pnas.60.4.1231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hellström I., Hellström K. E., Bill A. H., Pierce G. E., Yang J. P. Studies on cellular immunity to human neuroblastoma cells. Int J Cancer. 1970 Sep 15;6(2):172–188. doi: 10.1002/ijc.2910060205. [DOI] [PubMed] [Google Scholar]
  22. Hellström I., Hellström K. E., Evans C. A., Heppner G. H., Pierce G. E., Yang J. P. Serum-mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor-specific antigens. Proc Natl Acad Sci U S A. 1969 Feb;62(2):362–368. doi: 10.1073/pnas.62.2.362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Helson L., Fleisher M., Bethune V., Murphy M. L., Schwartz M. K. Urinary cystathionine, catecholamine, and metabolites in patients with neuroblastoma. Clin Chem. 1972 Jul;18(7):613–615. [PubMed] [Google Scholar]
  24. Helson L. Management of disseminated neuroblastoma. CA Cancer J Clin. 1975 Sep-Oct;25(5):264–277. doi: 10.3322/canjclin.25.5.264. [DOI] [PubMed] [Google Scholar]
  25. Heppner G. H., Stolbach L., Byrne M., Cummings F. J., McDonough E., Calabresi P. Cell-mediated and serum blocking reactivity to tumor antigens in patients with malignant melanoma. Int J Cancer. 1973 Mar 15;11(2):245–260. doi: 10.1002/ijc.2910110202. [DOI] [PubMed] [Google Scholar]
  26. Hoffken K., Meredith I. D., Robins R. A., Baldwin R. W., Davies C. J., Blamey R. W. Circulating immune complexes in patients with breast cancer. Br Med J. 1977 Jul 23;2(6081):218–220. doi: 10.1136/bmj.2.6081.218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Jose D. G., Seshadri R. Circulating immune complexes in human neuroblastoma: direct assay and role in blocking specific cellular immunity. Int J Cancer. 1974 Jun 15;13(6):824–838. doi: 10.1002/ijc.2910130610. [DOI] [PubMed] [Google Scholar]
  28. Jose D. G., Skvaril F. Serum inhibitors of cellular immunity in human neuroblastoma. IgG subclass of blocking activity. Int J Cancer. 1974 Feb 15;13(2):173–178. doi: 10.1002/ijc.2910130204. [DOI] [PubMed] [Google Scholar]
  29. Kaplan B. S., Klassen J., Gault M. H. Glomerular injury in patients with neoplasia. Annu Rev Med. 1976;27:117–125. doi: 10.1146/annurev.me.27.020176.001001. [DOI] [PubMed] [Google Scholar]
  30. Kávai M., Berényi E., Pálkovi E., Szegedi G. Letter: Immune complexes in Hodgkin's disease. Lancet. 1976 Jun 5;1(7971):1249–1249. doi: 10.1016/s0140-6736(76)92209-1. [DOI] [PubMed] [Google Scholar]
  31. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  32. Levin J., Tomasulo P. A., Oser R. S. Detection of endotoxin in human blood and demonstration of an inhibitor. J Lab Clin Med. 1970 Jun;75(6):903–911. [PubMed] [Google Scholar]
  33. Long J. C., Hall C. L., Brown C. A., Stamatos C., Weitzman S. A., Carey K. Binding of soluble immune complexes in serum of patients with Hodgkin's disease to tissue cultures derived from the tumor. N Engl J Med. 1977 Aug 11;297(6):295–299. doi: 10.1056/NEJM197708112970602. [DOI] [PubMed] [Google Scholar]
  34. Loughridge L. W., Lewis M. G. Nephrotic syndrome in malignant disease of non-renal origin. Lancet. 1971 Feb 6;1(7693):256–258. doi: 10.1016/s0140-6736(71)90999-8. [DOI] [PubMed] [Google Scholar]
  35. MacMillan R. W., Blanc W. B., Santulli T. V. Maturation of neuroblastoma to ganglioneuroma in lymph nodes. J Pediatr Surg. 1976 Jun;11(3):461–462. doi: 10.1016/s0022-3468(76)80204-7. [DOI] [PubMed] [Google Scholar]
  36. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  37. McConahey P. J., Dixon F. J. A method of trace iodination of proteins for immunologic studies. Int Arch Allergy Appl Immunol. 1966;29(2):185–189. doi: 10.1159/000229699. [DOI] [PubMed] [Google Scholar]
  38. Nydegger U. E., Zubler R. H., Gabay R., Joliat G., Karagevrekis C. H., Lambert P. H., Miescher P. A. Circulating complement breakdown products in patients with rheumatoid arthritis. Correlation between plasma C3d, circulating immune complexes, and clinical activity. J Clin Invest. 1977 May;59(5):862–868. doi: 10.1172/JCI108708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Oldstone M. B. Immune complexes in cancer: demonstration of complexes in mice bearing neuroblastomas. J Natl Cancer Inst. 1975 Jan;54(1):223–228. doi: 10.1093/jnci/54.1.223. [DOI] [PubMed] [Google Scholar]
  40. Oldstone M. B., Theofilopoulos A. N., Gunvén P., Klein G. Immune complexes associated with neoplasia: presence of Epstein-Barr virus antigen-antibody complexes in Burkitt's lymphoma. Intervirology. 1974;4(5):292–302. doi: 10.1159/000149862. [DOI] [PubMed] [Google Scholar]
  41. Ozawa T., Pluss R., Lacher J., Boedecker E., Guggenheim S., Hammond W., McIntosh R. Endogenous immune complex nephropathy associated with malignancy I. Studies on the nature and immunopathogenic significance of glomerular bound antigen and antibody, isolation and characterization of tumor specific antigen and antibody and circulating immune complexes. Q J Med. 1975 Oct;44(176):523–541. [PubMed] [Google Scholar]
  42. Rossen R. D., Reisberg M. A., Hersh E. M., Gutterman J. U. The C1q binding test for soluble immune complexes: clinical correlations obtained in patients with cancer. J Natl Cancer Inst. 1977 May;58(5):1205–1215. doi: 10.1093/jnci/58.5.1205. [DOI] [PubMed] [Google Scholar]
  43. Schutte M., DiCamelli R., Murphy P., Sadove M., Gewurz H. C3 proactivator (C3PA) as an acute phase reactant. Clin Exp Immunol. 1974 Oct;18(2):251–256. [PMC free article] [PubMed] [Google Scholar]
  44. Sjögren H. O., Hellström I., Bansal S. C., Hellström K. E. Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes. Proc Natl Acad Sci U S A. 1971 Jun;68(6):1372–1375. doi: 10.1073/pnas.68.6.1372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Sutherland J. C., Mardiney M. R., Jr Immune complex disease in the kidneys of lymphoma-leukemia patients: the presence of an oncornavirus-related antigen. J Natl Cancer Inst. 1973 Mar;50(3):633–644. doi: 10.1093/jnci/50.3.633. [DOI] [PubMed] [Google Scholar]
  46. Sutherland J. C., Markham R. V., Jr, Ramsey H. E., Mardiney M. R., Jr Subclinical immune complex nephritis in patients with Hodgkin's disease. Cancer Res. 1974 May;34(5):1179–1181. [PubMed] [Google Scholar]
  47. Tamerius J. D., Hellström I. In vitro demonstration of complement-dependent cytotoxic antibodies to Moloney sarcoma cells. J Immunol. 1974 Jun;112(6):1987–1996. [PubMed] [Google Scholar]
  48. Teshima H., Wanebo H., Pinsky C., Day N. K. Circulating immune complexes detected by 125I-Clq deviation test in sera of cancer patients. J Clin Invest. 1977 Jun;59(6):1134–1142. doi: 10.1172/JCI108737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Theofilopoulos A. N., Wilson C. B., Dixon F. J. The Raji cell radioimmune assay for detecting immune complexes in human sera. J Clin Invest. 1976 Jan;57(1):169–182. doi: 10.1172/JCI108257. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES